

Drug Monograph
Hydroquinone
40mg/g
(WYTOSTATE
TM)

November 2022

Marketing status:

Non-Approved

Application

Packager: KATSULA

PHARMA

Manufactured by: IFC

Skincare Portugal -

Produtos

Dermatológicos,

Unip., Ld


release v1.1



The purpose of KATSULA drug monographs are to provide a minimal comprehensive review of a approved drug application. The monographs will be updated if there are substancial changes.

Please note WYTOSTATE™ is not intended to diagnose, treat, cure, or prevent any disease.

W Y T O S T A T E TM
hydroquinone



Hydroquinone cream

40mg/g

skin whitening agent

1. NONMEDICINAL INGREDIENTS

- ketostearyalcohol alcohol emulsifying type B.
- Octyl methoxycinnamate.
- Cetyl alcohol.
- Macrogol ketostearilic ether.
- Isopropyl myristate.
- Polissorbato 20.
- Oleato of decile.
- Avobenzona;
- Propylene glycol
- Sodium metabisulphyte
- Methyl parahydroxybenzoate (E-223)
- Propyl parahydroxybenzoate (E-218)
- Disodium Edetate (E-216)
- Purified water

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each g of the product contains 40mg of hydroquinone.

3. PHARMACEUTICAL FORM

In total a 25g gel form, inside a aluminium container with a thread to open and close.

4. ACTION AND CLINICAL PHARMACOLOGY

Mechanism of action

Wytostate acts as double mechanism: the active substance + filters. The active substance, hidroquinona, causes alterations in the process of the creation of melanine causing progressive dyspigmentation and reversible by the enzymatic mechanism which it inhibits "tyrosinase inhibition" the very enzym which produces melanine.

It was proven that it is not production that is drastically reduced but melanine already produced itself is destroyed in the process, in combination with the UV rays filters causing a complete protection and preventing from skin from turning dark.

Pharmacodynamics

The application of hidroquinone over small cutaneous areas, and its slow absorvion through the skin and its fast metabolization and excretion through the urine make this substance not able to provoke systemic effects.

5. HOW TO USE

Apply a fine layer in areas in which the skin is brown 2 times a day. You are able to do this with risks at a minimum for 2 month. Above 2 months you should stop as risks of skin disorders increase with time.

KATSULA makes no warranties of any kind, expressed or implied, that the chemicals and/or suplies are merchantable or that they are fit for any particular purpose. In no event shall KATSULA be liable for consequential damages, nor shall KATSULA's liability on any claim for damages arising out of or connected with the sale, delivery or use of the chemicals and/or supplies exceed the purchase price of the chemicals and/or supplies. The buyer will not use the chemicals and/or supplies in violation of any local, state or federal law. The original customer, successors and assigns, agrees to hold KATSULA harmless from and will indemnify KATSULA from damages caused by the use of the chemicals and/or supplies.